Thursday, July 21, 2011

EMA concludes review on pioglitazone, says actos increases bladder cancer risk, but the confirmed benefits in diabetes are important, while bladder cancer is manageable by virtue of proper patient selection and periodic review

 The EMA said that CHMP had finished its review of pioglitazone and said that “there is a small increased risk of bladder cancer in patients taking” medicines which contain pioglitazone. Nevertheless, it “confirmed that these medicines remain a valid treatment option for certain patients with type 2 diabetes.” CHMP said that the small increased risk of bladder cancer “could be reduced by appropriate patient selection and exclusion, including a requirement for periodic review of the efficacy and safety of the individual patient’s treatment.”